


CLAIMS:


1. A compound:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1, or a pharmaceutically acceptable salt thereof.

3. A compound:



4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 3.

5. The compound of claim 1 for use in treating a CDK9-mediated disease in a patient.

6. The compound of claim 5, wherein the CDK9-mediated disease is a cancer caused by aberrant expression of MYC- or MCL-1, a hematologic malignancy, or a solid tumor.

7. The compound of claim 6, wherein the CDK9-mediated disease is acute myelogenous leukemia, primary peritoneal carcinoma, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute biphenotypic leukemia, advanced breast cancer, non-small cell lung cancer, or liver cancer.
8. The compound of claim 3 for use in treating a CDK9-mediated disease in a patient.
9. The compound of claim 8, wherein the CDK9-mediated disease is a cancer caused by aberrant expression of MYC- or MCL-1, a hematologic malignancy, or a solid tumor.
10. The compound of claim 9, wherein the CDK9-mediated disease is acute myelogenous leukemia, primary peritoneal carcinoma, chronic lymphocytic leukemia, relapsed multiple myeloma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute biphenotypic leukemia, advanced breast cancer, non-small cell lung cancer, or liver cancer.